The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Silvant Capital Management LLC

Silvant Capital Management LLC lessened its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 3.5% during the third quarter, Holdings Channel reports. The firm owned 50,878 shares of the medical device company’s stock after selling 1,822 shares during the period. Silvant Capital Management LLC’s holdings in Cooper Companies were worth $5,614,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of COO. Innealta Capital LLC acquired a new stake in shares of Cooper Companies in the second quarter valued at about $25,000. Covestor Ltd grew its holdings in Cooper Companies by 305.9% during the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 208 shares in the last quarter. Crewe Advisors LLC increased its stake in Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the period. Tortoise Investment Management LLC lifted its holdings in Cooper Companies by 75.4% in the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after buying an additional 169 shares in the last quarter. Finally, Clearstead Trust LLC purchased a new position in Cooper Companies in the 1st quarter valued at about $36,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Cooper Companies news, CAO Agostino Ricupati sold 1,601 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the transaction, the chief accounting officer now owns 4,818 shares in the company, valued at $520,488.54. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Brian G. Andrews sold 24,788 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares of the company’s stock, valued at approximately $700,422.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Agostino Ricupati sold 1,601 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares of the company’s stock, valued at approximately $520,488.54. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 256,373 shares of company stock worth $27,637,427. Company insiders own 2.00% of the company’s stock.

Cooper Companies Stock Up 1.1 %

COO opened at $105.85 on Friday. The stock has a fifty day moving average of $106.78 and a 200-day moving average of $97.06. The Cooper Companies, Inc. has a fifty-two week low of $78.63 and a fifty-two week high of $112.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The company has a market capitalization of $21.08 billion, a P/E ratio of 58.97, a P/E/G ratio of 2.52 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.84 earnings per share. On average, equities analysts expect that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on COO shares. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and increased their price target for the company from $107.00 to $115.00 in a report on Tuesday, July 16th. Morgan Stanley lifted their price target on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Piper Sandler upped their price objective on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, Robert W. Baird upped their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.